Table 2.
Association between clinicopathological variables and 17βHSD1/ 17βHSD2 status in 103 NSCLC patients
| 103 cases |
17βHSD1 |
|
17βHSD2 |
||||
|---|---|---|---|---|---|---|---|
| High n=51 | Low/Negative n=52 | P | High n=54 | Low/Negative n=49 | P | ||
| SEX |
Male |
31 |
31 |
|
36 |
26 |
|
| Female |
20 |
21 |
0.903 |
18 |
23 |
0.158 |
|
| Histology |
Adeno |
38 |
39 |
|
35 |
42 |
|
| SCC |
11 |
12 |
|
16 |
7 |
|
|
| Adeno squamous |
2 |
1 |
0.826 |
3 |
0 |
0.031 |
|
| Stage |
I |
28 |
40 |
|
27 |
41 |
|
| II |
7 |
2 |
|
7 |
2 |
|
|
| III |
15 |
8 |
|
18 |
5 |
|
|
| IV |
1 |
2 |
0.055 |
2 |
1 |
0.004 |
|
| pT |
pT1 |
20 |
27 |
|
18 |
29 |
|
| pT2 |
25 |
20 |
|
26 |
19 |
|
|
| pT3 |
3 |
2 |
|
4 |
1 |
|
|
| pT4 |
3 |
4 |
0.617 |
6 |
0 |
0.010 |
|
| pN |
pN0 |
34 |
44 |
|
36 |
42 |
|
| pN1 |
6 |
3 |
|
7 |
2 |
|
|
| pN2 |
11 |
5 |
0.100 |
11 |
5 |
0.065 |
|
| pM |
pM0 |
50 |
49 |
|
52 |
47 |
|
| pM1 |
1 |
3 |
0.306 |
2 |
2 |
0.921 |
|
| Diameter* |
|
15-65 (30) |
10-90 (27) |
0.156 |
18-75 (31.5) |
10-90 (24) |
0.002 |
| Ki-67 %* |
|
0-54.2 (17.6) |
0-47.2 (16.6) |
0.697 |
0-54.2 (18.3) |
0-47.2 (13.4) |
0.127 |
| ERα |
positive |
15 |
9 |
0.244 |
14 |
10 |
0.641 |
| negative |
37 |
42 |
|
40 |
39 |
|
|
| ERβ |
positive |
49 |
43 |
0.097 |
50 |
42 |
0.257 |
| negative |
3 |
8 |
|
4 |
7 |
|
|
| Aromatase |
positive |
47 |
39 |
0.057 |
47 |
39 |
0.309 |
| negative | 5 | 12 | 7 | 10 | |||
Statistical analysis was conducted by Fisher exact test, Wilcoxon rank sum test, and Pearson χ2 test.
* Data were continuous variables and the median with minimum-maximum values were presented.